Allergy Immunotherapies Market is expected to reach US$ 4,185.89 Mn by 2027

Allergy Immunotherapies Market for Sublingual Immunotherapy (SLIT) to Grow at Highest CAGR during 2020–2027

According to our new market research study on “Allergy Immunotherapies Market to 2027 – Global Analysis and Forecast – by Application and Distribution Channel,” the market is expected to reach US$ 4,185.89 million by 2027 from US$ 1,819.18 million in 2019. The market is estimated to grow with a CAGR of 11.1% from 2020 to 2027. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth.

Based on treatment, the market is segmented into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). In 2019, the subcutaneous immunotherapy (SCIT) held the largest share in the market and was forecasted to retain its dominance until 2027. This attributes to be the most efficient and most commonly used form of allergy immunotherapy. The medicine is useful in the treatment of allergic rhinitis, asthma, and stinging insect hypersensitivity. Moreover, SCIT has been productive in the management of more than one type of allergen. Hence, the adoption of SCIT is more than SLIT.

On the other hand, sublingual immunotherapy (SLIT) is expected to witness fastest growth rate owing to factors such as SLIT is anticipated to become a vital alternative for patients who cannot receive allergy shots. It is expected that liquid formulation would also be allowed for therapeutic use in the future. This would augment the increase of the SLIT segment in the forecasted period.

Factors such as growing prevalence of allergic disorders and technological advancements in sublingual dosage formulations. However, the market is likely to get impacted by the drawbacks associated with the use of allergy immunotherapy and regulatory variations across regions during the forecast period.

ALK-Abelló A/S, AIMMUNE THERAPEUTICS, INC., LETIPharma, Stallergenes Greer, HAL Allergy B.V, Anergis, DBV Technologies, Dermapharm Holding Allergy Therapeutics are among the leading companies operating in the allergy immunotherapies market.

Allergy Immunotherapies Market, by Region, 2019 (%)

---

Allergy Immunotherapies Market Size & Share | Forecast 2027

Download Free Sample

---

Allergy Immunotherapies Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Treatment (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT)); Allergy Type (Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, Others); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography

The Report Segments Global Allergy Immunotherapies Market as Follows:

By Treatment

• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)

By Allergy Type

• Allergic Rhinitis
• Asthma
• Food Allergy
• Venom Allergy
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • UK
  • Spain
  • Italy
• Asia Pacific (APAC)
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Middle East and Africa (MEA)
  • Saudi Arabia
  • UAE
  • South Africa
• South and Central America (SCAM)
  • Brazil
  • Argentina